Aquestive Therapeutics, Inc. · NASDAQ:AQST
Aquestive Therapeutics — Q1 2023 Earnings Presentation
11 slides from Aquestive Therapeutics's earnings presentation, May 2, 2023
Slide 1: Q1 2023 Earnings Supplemental Materials
Advancing medicines. Solving problems. Improving lives. Advancing medicines. Solving problems. Improving lives. Q1 2023 Earnings Supplemental Materials May 3, 2023 1
Slide 2: Disclaimer
Advancing medicines. Solving problems. Improving lives. ® Disclaimer This presentation contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 which are based on the beliefs and assumptions and on information currently available to the managem
Slide 3: Q1 2023 Earnings: Key Messages
Advancing medicines. Solving problems. Improving lives. Q1 2023 Earnings: Key Messages AnaphylmTM (AQST-109 - Epinephrine Sublingual Film) Proprietary trade name Anaphylm conditionally approved by the FDA Completed additional studies to identify the appropriate autoinjector RLDs Continuing to
Slide 4: Strong Start to 2023
Advancing medicines. Solving problems. Improving lives. 4 Strong Start to 2023… - First debt pre-payment of $3.8 million FEBRUARY - Presented positive data on Anaphylm at AAAAI - Second debt pre-payment of $1.9 million JANUARY - Indivior agreement amended and renewed - $11.5 million received - Settl
Slide 5: Continuing to Strengthen Our Cash Position
Advancing medicines. Solving problems. Improving lives. 5 Continuing to Strengthen Our Cash Position 14.7 17.7 18.6 27.3 26.9 0 5 10 15 20 25 30 Ending Cash Ending Cash by Quarter Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 All figures in USD millions
Slide 6: Debt Position Decreased in Q1 and Will Throughout 2023
Advancing medicines. Solving problems. Improving lives. 6 Debt Position Decreased in Q1 and Will Throughout 2023 51.5 42.4 39.0 34.4 29.8 0 10 20 30 40 50 60 Ending Cash Forecasted Debt by Quarter Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 All figures in USD millions
Slide 7: Manufacturing Operations
Advancing medicines. Solving problems. Improving lives. Manufacturing Operations 7
Slide 8: Manufacturing Operations Continues to Meet Expectations and Generate Cash Flow
Advancing medicines. Solving problems. Improving lives. Manufacturing Operations Continues to Meet Expectations and Generate Cash Flow 8 30,916 49,182 47,505 36,413 42,182 47,041 41,097 36,863 33,458 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 PHARMFILM® VOLUME (MILLIONS)
Slide 9: 2023 Outlook
Advancing medicines. Solving problems. Improving lives. 2023 Outlook 9
Slide 10: 2023 Outlook Update – Revised Guidance
Advancing medicines. Solving problems. Improving lives. 2023 Outlook Update – Revised Guidance 2023 Outlook as of May 2023 • Total revenues of approximately $42 to $46 million • Non-GAAP adjusted EBITDA loss of approximately $24 to $28 million 10
Slide 11: Thank You
Advancing medicines. Solving problems. Improving lives. Thank You
Aquestive Therapeutics — Q1 2023 Earnings Presentation on 6ix